ADVA
16.12.2020 17:02:35 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its technology has been selected for Germany’s first open radio access network (O-RAN) proof of concept (PoC). Conducted by Telefónica Germany / O2 , the field trial is a major step towards open and disaggregated RAN architectures. Built on Ensemble Activator , ADVA’s carrier-grade network operating system (NOS) running on Edgecore’s white box switches, and the OSA 5401 , ADVA’s pluggable grandmaster clock and GNSS receiver, the PoC shows how Telefónica Germany / O2 can build disaggregated and vendor-neutral mobile networks that significantly reduce deployment and operational costs. The unique combination of ADVA’s expertise in carrier-grade NOS technology and its Oscilloquartz synchronization solution has enabled this PoC to go beyond other such trials and address the most stringent network timing requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005737/en/
“This PoC is an important stage in our journey towards open 5G networking. It shows how we can achieve the scale and agility needed for the widespread rollout of next-generation mobile services and underlines the benefits of vendor collaboration and interoperability,” commented Matthias Sauder, director, mobile access network, Telefónica Germany / O2 . “With this open RAN pilot in our O2 live network, we’re highlighting what can be achieved when industry leaders from across the value chain cooperate closely together in an open environment. We’re also proving that a disaggregated model built on affordable software-empowered hardware can deliver transport infrastructure with new levels of efficiency – for 4G as well as 5G networks in the future.”
The multi-vendor PoC is built on ADVA’s feature-rich Ensemble Activator running on Edgecore’s switching device. Developed as part of the Telecom Infra Project (TIP), the software frees mobile network operators (MNOs) from closed proprietary systems and enables them to create vendor-neutral disaggregated infrastructure with best-of-breed components. The OSA 5401’s time synchronization capabilities are also central to the Telefónica Germany / O2 trial, including its ability to send PTP sync information and corresponding messages with precise timestamping data. The OSA 5401 also makes this advanced operation compatible with 5G radio access points from third-party suppliers and augments the accurate timing needed.
“By harnessing our high-performance NOS and compact timing solution, Telefónica Germany / O2 is taking a big step towards open and disaggregated 5G networking. This PoC shows how it will be able to utilize RAN technology from multiple vendors and leverage the full benefits of separated software and hardware,” said Eli Angel, VP, product line management, ADVA. “As we’re proving in multiple real-world trials with major MNOs, our Ensemble Activator is the ideal choice for turning third-party white box switches from a wide range of suppliers into disaggregated cell site gateways (DCSGs). What’s more, our OSA 5401 provides the strict timing and interoperability needed for an open model. To put it simply, our technology is the key to making open RAN work.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005737/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom